JP2018523684A5 - - Google Patents

Info

Publication number

JP2018523684A5

JP2018523684A5 JP2018508686A JP2018508686A JP2018523684A5 JP 2018523684 A5 JP2018523684 A5 JP 2018523684A5 JP 2018508686 A JP2018508686 A JP 2018508686A JP 2018508686 A JP2018508686 A JP 2018508686A JP 2018523684 A5 JP2018523684 A5 JP 2018523684A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

patient

composition according

antibody

weeks

Prior art date

2016-08-17

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 238000002617 apheresis Methods 0.000 claims description 26
• 102000025171 antigen binding proteins Human genes 0.000 claims description 8
• 108091000831 antigen binding proteins Proteins 0.000 claims description 8
• 108010028554 LDL Cholesterol Proteins 0.000 claims description 7
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
• 238000000034 method Methods 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 24
• 108090001030 Lipoproteins Proteins 0.000 claims 13
• 102000004895 Lipoproteins Human genes 0.000 claims 13
• 229940122392 PCSK9 inhibitor Drugs 0.000 claims 11
• 238000002560 therapeutic procedure Methods 0.000 claims 7
• 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims 6
• 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims 6
• 239000000427 antigen Substances 0.000 claims 5
• 102000036639 antigens Human genes 0.000 claims 5
• 108091007433 antigens Proteins 0.000 claims 5
• 239000012634 fragment Substances 0.000 claims 5
• 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 4
• 108010007622 LDL Lipoproteins Proteins 0.000 claims 3
• 210000002966 serum Anatomy 0.000 claims 3
• 208000030673 Homozygous familial hypercholesterolemia Diseases 0.000 claims 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
• 150000002632 lipids Chemical class 0.000 claims 2
• 238000012986 modification Methods 0.000 claims 2
• 230000004048 modification Effects 0.000 claims 2
• 108010027006 Apolipoproteins B Proteins 0.000 claims 1
• 102000018616 Apolipoproteins B Human genes 0.000 claims 1
• 108010023302 HDL Cholesterol Proteins 0.000 claims 1
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
• 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
• 239000008280 blood Substances 0.000 claims 1
• 230000008081 blood perfusion Effects 0.000 claims 1
• 229950011350 bococizumab Drugs 0.000 claims 1
• 235000012000 cholesterol Nutrition 0.000 claims 1
• 229960000633 dextran sulfate Drugs 0.000 claims 1
• 238000001914 filtration Methods 0.000 claims 1
• 229960002897 heparin Drugs 0.000 claims 1
• 229920000669 heparin Polymers 0.000 claims 1
• 230000010412 perfusion Effects 0.000 claims 1
• 238000001556 precipitation Methods 0.000 claims 1
• 238000002203 pretreatment Methods 0.000 claims 1
• 102000004169 proteins and genes Human genes 0.000 claims 1
• 108090000623 proteins and genes Proteins 0.000 claims 1
• 229950009885 ralpancizumab Drugs 0.000 claims 1
• 238000001179 sorption measurement Methods 0.000 claims 1
• 229940068196 placebo Drugs 0.000 description 7
• 239000000902 placebo Substances 0.000 description 7
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• 102220365045 c.89T>A Human genes 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1